Neurizon Therapeutics (ASX:NUZ) Operating Margin %: 0.00% (As of Dec. 2025)


What is Neurizon Therapeutics Operating Margin %?

Neurizon Therapeutics ASX:NUZ Operating Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Neurizon Therapeutics ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Neurizon Therapeutics's Operating Income for the six months ended in Dec. 2025 was A$-11.41 Mil. Neurizon Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Neurizon Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Neurizon Therapeutics's Operating Margin % or its related term are showing as below:


ASX:NUZ's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.77
* Ranked among companies with meaningful Operating Margin % only.

Neurizon Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Neurizon Therapeutics's Operating Income for the six months ended in Dec. 2025 was A$-11.41 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$-20.85 Mil.


Neurizon Therapeutics  (ASX:NUZ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Neurizon Therapeutics Operating Margin % Related Terms


Neurizon Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Operating Margin % Chart

Neurizon Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -130.42 -81.31 -131.06 0.00 0.00

Neurizon Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:NUZ vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Neurizon Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurizon Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Operating Margin % falls into.



Neurizon Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Neurizon Therapeutics's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=-18.476 / 0
= %

Neurizon Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-11.407 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Neurizon Therapeutics (ASX:NUZ) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Neurizon Therapeutics and its competitors. According to the industry distribution chart, Neurizon Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Neurizon Therapeutics' Operating Margin % too high?
Neurizon Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Neurizon Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neurizon Therapeutics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurizon Therapeutics ranks #999999 out of 945 companies for Operating Margin %. This places Neurizon Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Neurizon Therapeutics and its competitors. Neurizon Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (ASX:NUZ) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Neurizon Therapeutics (ASX:NUZ), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:Germany
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).